Example of HTV strategy (for GPR103 antagonist in obesity and weight management)
| Timescale | Project Start | 6 mo | 12 mo | 18+ mo |
|---|---|---|---|---|
| HTV status | Low (level 9) | Low (level 8) | Medium (level 6) | High (level 2) |
| Target present in correct tissue | Target/pathway is altered in healthy vs. diseased population | Pathway-related effect in clinical challenge model | Clinical tool is hitting the target | |
| Evidence | mRNA expression data demonstrated GPR103 expression in human brain, including the hypothalamus, and QRFP (endogenous ligand) expression and binding in human hypothalamic neurons | |||
| Key activities | Is there evidence that the GPR103 pathway and/or its ligands are dysregulated in obese patients (in silico analysis of internal and external databases)? | Is there evidence that the GPR103 receptor ligands QRFP26 and QRFP43 are present in either the circulation or cerebrospinal fluid at different levels in humans between fasting and fed states? | Does an exploratory clinical tool GPR103 antagonist reduce food intake in humans? |
QRFP, pyroglutamylated RFamide peptide.